Literature DB >> 7425603

Intrarenal distribution of trimethoprim and sulfamethoxazole.

S Trottier, M G Bergeron, C Lessard.   

Abstract

In the present study, rats were given trimethoprim (TMP, 10 mg/kg), sulfamethoxazole (SMZ, 50 mg/kg), or a combination of the respective doses of TMP and SMZ. Thirty-six rats received each of the drugs studied. Six recipients of a compound (or mixture) were evaluated hourly, from 1 to 6 h after intraperitoneal injection of the agent. At each timed interval, serum, urine, cortex, medulla, and papilla were analyzed for drug content. Peak serum values of 1.1 microgram of TMP and 131.1 microgram of active SMZ (nonacetylated sulfonamide) per ml were observed after injection of the combination TMP-SMZ. Although the cortical, medullary, and papillary TMP concentrations were severalfold higher than the respective serum values (P < 0.01), microbiologically active SMZ did not concentrate in the renal parenchyma and was found in lower concentration there than in the serum (P < 0.01). The levels of SMZ in all parts of the kidney of animals which received the mixture SMZ-TMP were lower than those detected in the animals which were given SMZ alone. The average ratio of active SMZ to TMP within the medulla and the papilla was less than 20 to 1 in the first 2 h. The intrarenal distribution of these drugs may have therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7425603      PMCID: PMC283795          DOI: 10.1128/AAC.17.3.383

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  18 in total

1.  Pharmacokinetic profile of trimethoprim-sulfamethoxazole in man.

Authors:  S A Kaplan; R E Weinfeld; C W Abruzzo; K McFaden; M L Jack; L Weissman
Journal:  J Infect Dis       Date:  1973-11       Impact factor: 5.226

2.  Human pharmacokinetics of a sulfamethoxazole-trimethoprim combination.

Authors:  T Bergan; E K Brodwall
Journal:  Acta Med Scand       Date:  1972-12

3.  APL computer program for the analytical and numerical integration of hormonal disappearance data.

Authors:  M Normand
Journal:  Can J Physiol Pharmacol       Date:  1972-08       Impact factor: 2.273

4.  Intrarenal distribution of penicillin, cephalothin, ampicillin and oxytetracycline during varied states of hydration.

Authors:  A Whelton; D G Sapir; G G Carter; J Kramer; W G Walker
Journal:  J Pharmacol Exp Ther       Date:  1971-11       Impact factor: 4.030

5.  Trimethoprim, a sulphonamide potentiator.

Authors:  S R Bushby; G H Hitchings
Journal:  Br J Pharmacol Chemother       Date:  1968-05

6.  The renal handling of trimethoprim and sulphamethoxazole in man.

Authors:  P Sharpstone
Journal:  Postgrad Med J       Date:  1969-11       Impact factor: 2.401

7.  Assay and pharmacokinetics of trimethoprim in man and animals.

Authors:  D E Schwartz; W H Ziegler
Journal:  Postgrad Med J       Date:  1969-11       Impact factor: 2.401

8.  Numerical versus analytical integration of hormonal disappearance data.

Authors:  M Normand; C Fortier
Journal:  Can J Physiol Pharmacol       Date:  1970-05       Impact factor: 2.273

9.  Pharmacokinetics of sulfamethoxazole plus trimethoprim in man and their distribution in the rat.

Authors:  D E Schwartz; J Rieder
Journal:  Chemotherapy       Date:  1970       Impact factor: 2.544

10.  Quantitative determination of the bacteriostatically active fraction of sulfonamides and the sum of their inactive metabolites in the body fluids.

Authors:  J Rieder
Journal:  Chemotherapy       Date:  1972       Impact factor: 2.544

View more
  2 in total

1.  Intrarenal concentrations of ampicillin in acute pyelonephritis.

Authors:  S Trottier; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

2.  Effects of sulfamethizole and amdinocillin against Escherichia coli strains (with various susceptibilities) in an ascending urinary tract infection mouse model.

Authors:  M B Kerrn; N Frimodt-Møller; F Espersen
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.